CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
about
Idiotype vaccination for Non-Hodgkin lymphomaRadiotherapy for advanced-stage aggressive non-Hodgkin lymphomaAdverse effects of biologics: a network meta-analysis and Cochrane overviewIdiotype vaccination for Non-Hodgkin lymphomaAre we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?Chemotherapy combinations with monoclonal antibodies in non-Hodgkin's lymphomaPhase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkersTargeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and FuturePrimary Non-Hodgkin's Lymphoma of the Vulva: A Case Report and Literature ReviewCurrent trends in the treatment of primary mediastinal large B-cell lymphoma - an overviewCurrent challenges and novel treatment strategies in double hit lymphomasEpstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developmentsThe role of gender in patients with diffuse large B cell lymphoma treated with rituximab-containing regimens: a meta-analysisRadiotherapy and "new" drugs-new side effects?Treatment of diffuse large B cell lymphomaRole of microRNA deregulation in the pathogenesis of diffuse large B-cell lymphoma (DLBCL)Rituximab treatment strategy for patients with diffuse large B-cell lymphoma after first-line therapy: a systematic review and meta-analysisHematopoietic cell transplantation for B-cell lymphoma: an updateNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewInterim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era.Integrative systems medicine approaches to identify molecular targets in lymphoid malignanciesEvolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent updateRadiotherapy for Non-Hodgkin's lymphoma: still standard practice and not an outdated treatment optionApproach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentaryHomozygous A polymorphism of the complement C1qA276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOPNovel CD20 monoclonal antibodies for lymphoma therapyRituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual MeetingMeta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents.Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma: analysis of web-based data from the Korean Lymphoma Working Party Registry.Exploring Big Data in Hematological Malignancies: Challenges and Opportunities.Blunt tools, burning questions: using cancer registry data to study relapsed/refractory lymphoma.High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351.Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports projectMultivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study.Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.Radioimmunotherapy with (131)I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL).Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study.
P2860
Q24186272-A2E07297-64D5-4F82-A2A8-50199A88B03DQ24187708-50F7B919-4EF5-4DDA-B3F3-02A9F22D6B66Q24234197-0BB556CC-4FA0-44A9-9A21-9BE99C83D8F1Q24235281-4A5520A3-CEF6-42D6-9504-2949252EA6EAQ24597424-2EF4BE8B-A1D2-490B-BEE2-A9341B9BBF6EQ24633714-766DD7F4-6518-440D-9F01-8AE2921C20A3Q24646379-B6892066-0DCF-47ED-B0DB-FC24077F05CFQ26746934-24528CA7-EDB7-40BE-A201-B2180483A9D0Q26766569-956F5981-3D94-4548-955E-79D86522ECBEQ26769596-AECE85E5-4C1A-47AC-8CFB-07E1F8AD31DCQ26770385-17979277-F938-40B0-9AA3-A68E172FB7EEQ26775442-DB6B3E39-6FF0-4D27-B949-C265340DFD3CQ26795818-F6F2B228-77D4-4831-89C0-5F62BFBCDB09Q26861498-3C6D27E3-7E3E-43A1-A918-2366A981074AQ27006062-5638B262-CC32-4CB8-866D-A6C1CC1C3E5AQ27016561-8A8DDCF7-7190-4585-8E9D-16D440204A58Q27025272-8F9B796B-F728-4481-AE40-7F2067F63AD2Q27026617-F9C7F6A4-20CF-4B05-8E5C-BB74BCD9D6FAQ27304386-2168C330-DCB0-42C1-B273-B563D4FB6F6BQ27314782-A2B52A26-9FDD-481B-9C6F-02E30961CF9BQ28067817-7B6617C2-D7FE-4C23-BCB9-B6D669FBE2EFQ28078869-A8724C2E-EB94-44DA-9599-2419D7ED7AF9Q28079951-BA2E3CCD-620C-4A1C-85AF-217B53E55386Q28088365-FFFE4BA7-C532-401C-9116-86FAA7F0AB84Q28389577-91D16113-7001-4A3D-918A-02496B98EB2CQ28390112-9C762757-37C7-4796-9A55-13CBDA080E9FQ28390181-B35653F2-AEE8-4730-923E-1F9A1DBC53F5Q30249335-8FED8314-03AE-4880-ADA7-EF68B4C33D9AQ30275206-1E5C80B6-875E-4E77-9B59-F1DAD291F930Q30653421-11DD4DE8-B275-43AC-97D0-E8C9B1141958Q31095966-B23D2733-1E95-4E9D-A31F-9FA093B71123Q31145054-B275D2E7-10E6-4A50-9799-0588AEA17C88Q33375173-F19D4F1D-DB9B-4E6D-B9A7-37A8616F35ACQ33377327-35068CC1-5C25-487A-8576-B6BBE81F6F1DQ33383576-9F0DB930-45F7-4F41-8166-AB68CA70A7E4Q33389472-21A0AF44-55E2-46ED-A544-7AA4C03B32BFQ33392784-9FAE01E7-0FA0-49ED-9C94-B7D39F949861Q33395360-0A9120DB-676E-4A8F-A53C-65D71D89B9E6Q33395564-1E7A15E1-1F88-45C9-8270-A46AE66265C2Q33396036-2DFEEB41-F9D2-4706-9753-E03CABDF8D03
P2860
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
CHOP-like chemotherapy plus ri ...... ernational Trial (MInT) Group.
@ast
CHOP-like chemotherapy plus ri ...... ernational Trial (MInT) Group.
@en
CHOP-like chemotherapy plus ri ...... e MabThera International Trial
@nl
type
label
CHOP-like chemotherapy plus ri ...... ernational Trial (MInT) Group.
@ast
CHOP-like chemotherapy plus ri ...... ernational Trial (MInT) Group.
@en
CHOP-like chemotherapy plus ri ...... e MabThera International Trial
@nl
prefLabel
CHOP-like chemotherapy plus ri ...... ernational Trial (MInT) Group.
@ast
CHOP-like chemotherapy plus ri ...... ernational Trial (MInT) Group.
@en
CHOP-like chemotherapy plus ri ...... e MabThera International Trial
@nl
P2093
P50
P1433
P1476
CHOP-like chemotherapy plus ri ...... ernational Trial (MInT) Group.
@en
P2093
Adriana Scheliga
Anders Osterborg
Armando López-Guillermo
Claudia Corrado
Devinder Gill
Evelyn Kuhnt
Jan Walewski
Kevin Imrie
MabThera International Trial Group
P304
P356
10.1016/S1470-2045(06)70664-7
P577
2006-05-01T00:00:00Z